TY - JOUR
T1 - Detection of t(2;5) in anaplastic large cell lymphoma
T2 - Comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue
AU - Cataldo, Kimberley A.
AU - Jalal, Syed M.
AU - Law, Mark E.
AU - Ansell, Stephen M.
AU - Inwards, David J.
AU - Fine, Miriam
AU - Arber, Daniel A.
AU - Pulford, Karen A.
AU - Strickler, John G.
PY - 1999/11/1
Y1 - 1999/11/1
N2 - Anaplastic large cell lymphoma (ALCL) is associated with the t(2;5)(p23;q35) translocation involving the anaplastic lymphoma kinase gene (ALK) and the nucleophosmin gene (NPM), which result in expression of a novel fusion protein, NPM-ALK (p80). Clinicopathologic studies have shown that ALK expression in ALCL is associated with improved 5-year survival rates when compared with ALCL lacking ALK expression. This study used paraffin-embedded tissue to compare interphase fluorescence in situ hybridization (FISH) and reverse transcriptase-polymerase chain reaction (RT-PCR) for the detection of t(2;5) with immunohistochemical analysis for the detection of ALK protein expression in 27 patients with CD30-positive ALCLs. ALK protein expression was detected with ALK1 antibody in 14 of the 27 patients. The neoplastic cells in 13 of these 14 lymphomas reacted with the p80(NPM/ALK) antibody. FISH, using a two-color ALK DNA probe, correlated 100% with the immunohistochemical results: a translocation involving the ALK gene was detected in all 14 lymphomas that reacted with anti-ALK1. RT-PCR, performed on 21 lymphomas, detected NPM-ALK mRNA in five of the lymphomas, all of which reacted with anti-ALK1 and showed ALK gene rearrangement by FISH. Lymphomas showing ALK1 reactivity occurred in a younger patient population (median age, 19.5 years) and were associated with improved 5-year survival rates (84%), as compared with lymphomas lacking ALK1 reactivity (median age, 68.0 years; 5- year survival rate, 35%; p = 0.008). We conclude that immunohistochemical studies, using antibody ALK1, and FISH for ALK gene rearrangement are equally effective for identifying patients with ALCL who have a favorable clinical outcome.
AB - Anaplastic large cell lymphoma (ALCL) is associated with the t(2;5)(p23;q35) translocation involving the anaplastic lymphoma kinase gene (ALK) and the nucleophosmin gene (NPM), which result in expression of a novel fusion protein, NPM-ALK (p80). Clinicopathologic studies have shown that ALK expression in ALCL is associated with improved 5-year survival rates when compared with ALCL lacking ALK expression. This study used paraffin-embedded tissue to compare interphase fluorescence in situ hybridization (FISH) and reverse transcriptase-polymerase chain reaction (RT-PCR) for the detection of t(2;5) with immunohistochemical analysis for the detection of ALK protein expression in 27 patients with CD30-positive ALCLs. ALK protein expression was detected with ALK1 antibody in 14 of the 27 patients. The neoplastic cells in 13 of these 14 lymphomas reacted with the p80(NPM/ALK) antibody. FISH, using a two-color ALK DNA probe, correlated 100% with the immunohistochemical results: a translocation involving the ALK gene was detected in all 14 lymphomas that reacted with anti-ALK1. RT-PCR, performed on 21 lymphomas, detected NPM-ALK mRNA in five of the lymphomas, all of which reacted with anti-ALK1 and showed ALK gene rearrangement by FISH. Lymphomas showing ALK1 reactivity occurred in a younger patient population (median age, 19.5 years) and were associated with improved 5-year survival rates (84%), as compared with lymphomas lacking ALK1 reactivity (median age, 68.0 years; 5- year survival rate, 35%; p = 0.008). We conclude that immunohistochemical studies, using antibody ALK1, and FISH for ALK gene rearrangement are equally effective for identifying patients with ALCL who have a favorable clinical outcome.
KW - Anaplastic lymphoma
KW - Anaplastic lymphoma kinase
KW - Fluorescence in situ hybridization
KW - Reverse transcriptase-polymerase chain reaction
UR - http://www.scopus.com/inward/record.url?scp=0032752921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032752921&partnerID=8YFLogxK
U2 - 10.1097/00000478-199911000-00009
DO - 10.1097/00000478-199911000-00009
M3 - Article
C2 - 10555007
AN - SCOPUS:0032752921
SN - 0147-5185
VL - 23
SP - 1386
EP - 1392
JO - American Journal of Surgical Pathology
JF - American Journal of Surgical Pathology
IS - 11
ER -